S&P 500   3,854.32 (+0.06%)
DOW   31,223.73 (+0.11%)
QQQ   324.93 (+0.36%)
AAPL   133.84 (+1.37%)
MSFT   224.50 (+0.07%)
FB   269.20 (+0.64%)
GOOGL   1,890.21 (+0.54%)
AMZN   3,293.80 (+0.93%)
TSLA   853.78 (+0.39%)
NVDA   534.85 (+0.04%)
BABA   263.79 (-0.64%)
CGC   33.55 (-0.24%)
GE   11.41 (+0.18%)
MU   84.00 (+0.60%)
AMD   89.06 (+0.35%)
NIO   57.09 (-1.07%)
T   28.97 (+0.03%)
F   11.39 (+4.88%)
ACB   11.41 (-1.13%)
BA   212.00 (+0.26%)
DIS   174.61 (+0.56%)
NFLX   582.25 (-0.70%)
GILD   67.35 (-0.94%)
S&P 500   3,854.32 (+0.06%)
DOW   31,223.73 (+0.11%)
QQQ   324.93 (+0.36%)
AAPL   133.84 (+1.37%)
MSFT   224.50 (+0.07%)
FB   269.20 (+0.64%)
GOOGL   1,890.21 (+0.54%)
AMZN   3,293.80 (+0.93%)
TSLA   853.78 (+0.39%)
NVDA   534.85 (+0.04%)
BABA   263.79 (-0.64%)
CGC   33.55 (-0.24%)
GE   11.41 (+0.18%)
MU   84.00 (+0.60%)
AMD   89.06 (+0.35%)
NIO   57.09 (-1.07%)
T   28.97 (+0.03%)
F   11.39 (+4.88%)
ACB   11.41 (-1.13%)
BA   212.00 (+0.26%)
DIS   174.61 (+0.56%)
NFLX   582.25 (-0.70%)
GILD   67.35 (-0.94%)
S&P 500   3,854.32 (+0.06%)
DOW   31,223.73 (+0.11%)
QQQ   324.93 (+0.36%)
AAPL   133.84 (+1.37%)
MSFT   224.50 (+0.07%)
FB   269.20 (+0.64%)
GOOGL   1,890.21 (+0.54%)
AMZN   3,293.80 (+0.93%)
TSLA   853.78 (+0.39%)
NVDA   534.85 (+0.04%)
BABA   263.79 (-0.64%)
CGC   33.55 (-0.24%)
GE   11.41 (+0.18%)
MU   84.00 (+0.60%)
AMD   89.06 (+0.35%)
NIO   57.09 (-1.07%)
T   28.97 (+0.03%)
F   11.39 (+4.88%)
ACB   11.41 (-1.13%)
BA   212.00 (+0.26%)
DIS   174.61 (+0.56%)
NFLX   582.25 (-0.70%)
GILD   67.35 (-0.94%)
S&P 500   3,854.32 (+0.06%)
DOW   31,223.73 (+0.11%)
QQQ   324.93 (+0.36%)
AAPL   133.84 (+1.37%)
MSFT   224.50 (+0.07%)
FB   269.20 (+0.64%)
GOOGL   1,890.21 (+0.54%)
AMZN   3,293.80 (+0.93%)
TSLA   853.78 (+0.39%)
NVDA   534.85 (+0.04%)
BABA   263.79 (-0.64%)
CGC   33.55 (-0.24%)
GE   11.41 (+0.18%)
MU   84.00 (+0.60%)
AMD   89.06 (+0.35%)
NIO   57.09 (-1.07%)
T   28.97 (+0.03%)
F   11.39 (+4.88%)
ACB   11.41 (-1.13%)
BA   212.00 (+0.26%)
DIS   174.61 (+0.56%)
NFLX   582.25 (-0.70%)
GILD   67.35 (-0.94%)
Log in
NASDAQ:LIVN

LivaNova Stock Forecast, Price & News

$64.46
-1.84 (-2.78 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$63.61
Now: $64.46
$67.53
50-Day Range
$53.28
MA: $64.56
$68.74
52-Week Range
$33.40
Now: $64.46
$77.29
Volume394,653 shs
Average Volume450,563 shs
Market Capitalization$3.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.8
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CVÂ) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC has a research collaboration with Verily to gain insights into Vagus nerve stimulation impact on difficult-to-treat depression. The company was founded in 1987 and is headquartered in London, the United Kingdom.
LivaNova logo

MarketRank

Overall MarketRank

1.53 out of 5 stars

Medical Sector

396th out of 1,928 stocks

Electromedical Equipment Industry

9th out of 61 stocks

Analyst Opinion: 1.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LIVN
CUSIPN/A
Phone44-0-20-3325-0660
Employees4,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.08 billion
Cash Flow$5.51 per share
Book Value$28.59 per share

Profitability

Net Income$-155,180,000.00

Miscellaneous

Market Cap$3.13 billion
Next Earnings Date2/24/2021 (Confirmed)
OptionableOptionable
$64.46
-1.84 (-2.78 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LIVN News and Ratings via Email

Sign-up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











LivaNova (NASDAQ:LIVN) Frequently Asked Questions

How has LivaNova's stock price been impacted by COVID-19?

LivaNova's stock was trading at $62.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, LIVN shares have increased by 2.9% and is now trading at $64.46.
View which stocks have been most impacted by COVID-19
.

Is LivaNova a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LivaNova stock.
View analyst ratings for LivaNova
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than LivaNova?

Wall Street analysts have given LivaNova a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but LivaNova wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as LivaNova's CEO?

1,428 employees have rated LivaNova CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among LivaNova's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is LivaNova's next earnings date?

LivaNova is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for LivaNova
.

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) issued its quarterly earnings data on Thursday, October, 29th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.20 by $0.18. The firm earned $240.10 million during the quarter, compared to analyst estimates of $218.55 million. LivaNova had a positive return on equity of 5.55% and a negative net margin of 21.88%. The company's revenue was down 10.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.84 EPS.
View LivaNova's earnings history
.

What guidance has LivaNova issued on next quarter's earnings?

LivaNova issued an update on its FY20 earnings guidance on Thursday, October, 29th. The company provided earnings per share guidance of $1.15-1.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.19.

What price target have analysts set for LIVN?

7 analysts have issued 1 year price objectives for LivaNova's stock. Their forecasts range from $40.00 to $114.00. On average, they anticipate LivaNova's share price to reach $66.71 in the next twelve months. This suggests a possible upside of 3.5% from the stock's current price.
View analysts' price targets for LivaNova
or view Wall Street analyst' top-rated stocks.

Are investors shorting LivaNova?

LivaNova saw a increase in short interest in December. As of December 31st, there was short interest totaling 3,450,000 shares, an increase of 28.3% from the December 15th total of 2,690,000 shares. Based on an average trading volume of 509,700 shares, the days-to-cover ratio is presently 6.8 days.
View LivaNova's Short Interest
.

Who are some of LivaNova's key competitors?

What other stocks do shareholders of LivaNova own?

Who are LivaNova's key executives?

LivaNova's management team includes the following people:
  • Mr. Damien McDonald, CEO & Director (Age 55, Pay $1.57M)
  • Ms. Keyna Pidcock Skeffington, Sr. VP, Gen. Counsel & Corp. Sec. (Age 57, Pay $659.22k)
  • Mr. Alex Shvartsburg, Interim CFO and Corp. VP of Financial Planning, Analysis & International Region
  • Ms. Melissa Farina, VP of Investor Relations
  • Deanna Wilke, Director of Corp. Communications
  • Mr. Matthew Joseph Dodds III, Sr. VP of Corp. Devel.
  • Ms. Trui Hebbelinck, Chief HR Officer (Age 48)
  • Mr. Pritpal Shinmar, Sr. VP of Global Market Access (Age 63)
  • Dr. Bryan D. Olin, Sr. VP of Clinical, Quality Assurance & Regulatory Affairs (Age 53)
  • Mr. Paul R. Buckman, Pres of North America & GM of Transcatheter Mitral Valve Replacement (Age 64)

What is LivaNova's stock symbol?

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

Who are LivaNova's major shareholders?

LivaNova's stock is owned by a variety of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.39%), Wedge Capital Management L L P NC (0.37%), State of Alaska Department of Revenue (0.02%), Pacer Advisors Inc. (0.01%), OneAscent Financial Services LLC (0.01%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own LivaNova stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore, Thad Allen Huston and William A Kozy.
View institutional ownership trends for LivaNova
.

Which major investors are selling LivaNova stock?

LIVN stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Rhenman & Partners Asset Management AB, and State of Alaska Department of Revenue.
View insider buying and selling activity for LivaNova
or view top insider-selling stocks.

Which major investors are buying LivaNova stock?

LIVN stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., OneAscent Financial Services LLC, and Crossmark Global Holdings Inc.. Company insiders that have bought LivaNova stock in the last two years include Alfred J Novak, and William A Kozy.
View insider buying and selling activity for LivaNova
or or view top insider-buying stocks.

How do I buy shares of LivaNova?

Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is LivaNova's stock price today?

One share of LIVN stock can currently be purchased for approximately $64.46.

How big of a company is LivaNova?

LivaNova has a market capitalization of $3.13 billion and generates $1.08 billion in revenue each year. The company earns $-155,180,000.00 in net income (profit) each year or $3.08 on an earnings per share basis. LivaNova employs 4,000 workers across the globe.

What is LivaNova's official website?

The official website for LivaNova is www.livanova.com.

How can I contact LivaNova?

LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 44-0-20-3325-0660 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.